Skip to content

Drug interactions

Apalutamide + Brentuximab

Severity: Moderate

Apalutamide and Brentuximab: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Brentuximab vedotin releases the cytotoxic agent MMAE, which is a CYP3A4 substrate. Apalutamide is a strong CYP3A4 inducer and may lower MMAE exposure, potentially reducing antitumor efficacy.

What this interaction means in plain words

Apalutamide and Brentuximab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Apalutamide belongs to Endocrine; Brentuximab belongs to Oncology.

Evidence level: Low

Why it happens

Apalutamide induces CYP3A4, increasing metabolism of the released MMAE.

What to do

Monitor for reduced treatment response; consider an alternative to apalutamide if clinically feasible.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Apalutamide and Brentuximab, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Apalutamide with Brentuximab?

MediHelp rates the interaction as moderate. Apalutamide and Brentuximab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Brentuximab vedotin releases the cytotoxic agent MMAE, which is a CYP3A4 substrate. Apalutamide is a strong CYP3A4 inducer and may lower MMAE exposure, potentially reducing antitumor efficacy.

How serious is the interaction between Apalutamide and Brentuximab?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for reduced treatment response; consider an alternative to apalutamide if clinically feasible.

What other medicines interact with Brentuximab?

MediHelp also lists interactions of Brentuximab with, for example, Bleomycin, Dengue vaccine, Etrasimod. The full list is on the Brentuximab page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in